Iovance Biotherapeutics
IOVA
292 hedge funds and large institutions have $1.19B invested in Iovance Biotherapeutics in 2026 Q2 according to their latest regulatory filings, with 45 funds opening new positions, 130 increasing their positions, 65 reducing their positions, and 35 closing their positions.
100% more repeat investments, than reductions
Existing positions increased: 130 | Existing positions reduced: 65
29% more first-time investments, than exits
New positions opened: 45 | Existing positions closed: 35
26% more capital invested
Capital invested by funds: $944M → $1.19B (+$248M)
16% more call options, than puts
Call options by funds: $24M | Put options by funds: $20.8M
2% more funds holding
Funds holding: 286 → 292 (+6)
1.14% less ownership
Funds ownership: 65.32% → 64.18% (-1.1%)
33% less funds holding in top 10
Funds holding in top 10: 3 → 2 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
State Street
Boston,
Massachusetts
|
+$26.7M |
| 2 |
BlackRock
New York
|
+$22.3M |
| 3 |
Two Sigma Investments
New York
|
+$20.2M |
| 4 |
JAM
Jupiter Asset Management
London,
United Kingdom
|
+$17.2M |
| 5 |
Dimensional Fund Advisors
Austin,
Texas
|
+$14.5M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ICM
Invenomic Capital Management
Boston,
Massachusetts
|
-$26.6M |
| 2 |
D.E. Shaw & Co
New York
|
-$22.3M |
| 3 |
Goldman Sachs
New York
|
-$13.9M |
| 4 |
Bank of America
Charlotte,
North Carolina
|
-$13.3M |
| 5 |
Marshall Wace
London,
United Kingdom
|
-$8.8M |
IOVA Hedge Fund Activity: Q2 2026 in Review
292 of the 8,305 institutional investors tracked by Wall St. Rank reported a position in Iovance Biotherapeutics (IOVA) for Q2 2026, worth a combined $1.19B — up 26% from $944M a quarter earlier.
Buyers outnumbered sellers: 45 funds opened new IOVA positions and 35 closed out — a net gain of 10 holders — while 130 added to existing stakes and 65 trimmed.
The largest buyer was State Street, adding an estimated $26.7M. The largest seller was Invenomic Capital Management, cutting an estimated $26.6M.
- 292 institutional investors held Iovance Biotherapeutics (IOVA) as of Q2 2026, up from 286 in Q1 2026.
- Funds reported $1.19B of Iovance Biotherapeutics stock for Q2 2026, up 26% quarter-over-quarter.
- 45 funds opened new Iovance Biotherapeutics positions in Q2 2026 and 35 closed out, a net change of +10 holders.
- The largest Iovance Biotherapeutics buyer in Q2 2026 was State Street, an estimated $26.7M added.
- The largest Iovance Biotherapeutics seller in Q2 2026 was Invenomic Capital Management, an estimated $26.6M sold.
Based on aggregated 13F filings for Q2 2026.